ClinicalTrials.gg
CompletedNCT06640920Updated Aug 12, 2025

A Study to Investigate Efficacy and Safety of NSI-8226 in Healthy Participants

A Phase 1 interventional study of Cohort A and Cohort B in Healthy, sponsored by Uniquity One (UNI). Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Uniquity One (UNI) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2024, 2 years ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Apr 2024, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

A Phase 1 Randomized, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Bioavailability of NSI-8226 in Healthy Participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Uniquity One (UNI) is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

1. At the time of initial screening, in general good health (age 18 to 65 years);

Key Exclusion Criteria:

  1. Pregnancy or breastfeeding during the study.
  2. Chronic infection - Treatment with prohibited medications.
  3. Treatment with prohibited medications
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort A

    NSI-8226

    Biological: Cohort A

  • Experimental
    Cohort B

    NSI-8226

    Biological: Cohort B

  • Experimental
    Cohort C

    NSI-8226

    Biological: Cohort C

  • Experimental
    Cohort D

    NSI-8226

    Biological: Cohort D

Interventions

  • BiologicalCohort A

    Administered IV High dose

  • BiologicalCohort B

    Administered SC Low Dose

  • BiologicalCohort C

    Administered SC Mid Dose

  • BiologicalCohort D

    Administered SC High Dose

06

What researchers measure

Primary outcomes

  1. Safety and tolerability

    To evaluate the incidence of treatment emergent adverse events of NSI-8826 in healthy participants according to Common Terminology Criteria for Adverse Events (CTCAE) V4.0

    Time frame: 140 days

Secondary outcomes

  1. Absolute bioavailability

    Pharmacokinetics (PK) and absolute bioavailability of NSI-8226 in healthy participants.

    Time frame: 140 days

  2. Concentration of immunogenicity

    Immunogenicity profile of NSI-8226 in healthy participants.

    Time frame: 140 days

  3. Parameters in healthy participants

    Pharmacodynamic (PD) parameters of NSI-8226 in healthy participants.

    Time frame: 140 days

07

Study locations

1 site
  • Research Site
    Cincinnati, Ohio 45227, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Oct 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2024
First posted
Oct 15, 2024
StartActual
Apr 29, 2024
Primary completionActual
Oct 29, 2024
CompletionActual
Oct 29, 2024
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06640920
Lead sponsor
Uniquity One (UNI)
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Apr 29, 2024
Primary completion
Oct 29, 2024
Completion
Oct 29, 2024
Last update
Aug 12, 2025

Study contacts

Andrew W Lee, MD
study chair · Vice President, Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion